Heart, Lung and Circulation
Volume 19, Issue 2 , Pages 90-92 , February 2010

Cardiac Troponin I Levels and Alveolar-arterial Oxygen Gradient in Patients with Community-acquired Pneumonia

  • Mahmoud Q. Moammar, MD

      Affiliations

    • Division of Pulmonary Medicine, Department of Internal Medicine, St. Joseph's Regional Medical Center, Paterson, NJ, United States
    • School of Health and Medical Sciences, Seton Hall University, South Orange, NJ, United States
    • ,
  • Muhammad I. Ali, MD

      Affiliations

    • Division of Pulmonary Medicine, Department of Internal Medicine, St. Joseph's Regional Medical Center, Paterson, NJ, United States
    • ,
  • Nader A. Mahmood, MD

      Affiliations

    • Division of Pulmonary Medicine, Department of Internal Medicine, St. Joseph's Regional Medical Center, Paterson, NJ, United States
    • ,
  • Vincent A. DeBari, PhD

      Affiliations

    • School of Health and Medical Sciences, Seton Hall University, South Orange, NJ, United States
    • Corresponding Author InformationCorresponding author.
    • ,
  • M. Anees Khan, MD

      Affiliations

    • Division of Pulmonary Medicine, Department of Internal Medicine, St. Joseph's Regional Medical Center, Paterson, NJ, United States
    • School of Health and Medical Sciences, Seton Hall University, South Orange, NJ, United States

Received 8 July 2009 ,Revised 25 August 2009 ,Accepted 27 August 2009.

References 

  1. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382
  2. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Eng J Med. 1997;336:243–250
  3. Christ-Crain M, Stolz D, Jutla S, Couppis O, Müller C, Bingisser R, et al. Free and total cortisol levels as predictors as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;176:913–920
  4. Christ-Crain M, Morgenthaler NG, Stolz D, Müller C, Bingisser R, Harbarth S, et al. Pro-adrenomodulin to predict severity and outcome in community-acquired pneumonia. Crit Care. 2006;10:R96;[ISRCTNO4176397]
  5. Christ-Crain M, Breidthardt T, Stolz D, Zobrist K, Bingisser R, Miedinger D, et al. Use of B-type natriuretic peptide in risk stratification of community-acquired pneumonia. J Intern Med. 2008;264:166–176
  6. Matsuo K, Nishikimi T, Yutani C, Kurita T, Shimizu W, Taguchi A, et al. Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. Circulation. 1998;98:2433–2440
  7. Moammar MQ, Azam HM, Blamoun AI, Rashid AO, Ismail M, Khan MA, et al. Alveolar-arterial oxygen gradient, pneumonia severity index and outcomes in patients with community-acquired pneumonia. Clin Exp Pharmacol Physiol. 2008;35:1032–1037
  8. Phua J, Koay ES, Zhang D, Tai LK, Boo XL, Lim KC, et al. Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections. Eur Respir J. 2006;28:695–702
  9. Tejera A, Santolaria F, Diez ML, Alemán-Valls MR, González-Reimers E, Martínez-Riera A, et al. Prognosis of community-acquired pneumonia: value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine. 2007;38:117–123
  10. Prat C, Lacoma A, Dominguez J, Papassotiriou J, Morgenthaler NG, Andreo F, et al. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. J Infect. 2007;55:400–407
  11. Müller B, Morgenthaler N, Stolz D, Schuetz P, Müller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory infections. Eur J Clin Invest. 2007;37:145–152

PII: S1443-9506(09)01057-9

doi: 10.1016/j.hlc.2009.08.009

Heart, Lung and Circulation
Volume 19, Issue 2 , Pages 90-92 , February 2010

Article Tools

* Image Usage & Resolution